BioXcel Therapeutics (BTAI) Projected to Post Quarterly Earnings on Tuesday

BioXcel Therapeutics (NASDAQ:BTAI) is expected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect BioXcel Therapeutics to post earnings of ($4.36) per share and revenue of $0.72 million for the quarter.

BioXcel Therapeutics Price Performance

NASDAQ:BTAI opened at $3.75 on Tuesday. The firm’s fifty day moving average price is $4.62 and its 200 day moving average price is $7.45. BioXcel Therapeutics has a 1-year low of $1.72 and a 1-year high of $52.80. The firm has a market cap of $11.63 million, a price-to-earnings ratio of -0.11 and a beta of -0.01.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BTAI. Canaccord Genuity Group lowered their price objective on shares of BioXcel Therapeutics from $112.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. HC Wainwright cut their target price on shares of BioXcel Therapeutics from $80.00 to $48.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Finally, Bank of America reissued an “underperform” rating and issued a $4.00 target price (down previously from $112.00) on shares of BioXcel Therapeutics in a research note on Tuesday, January 7th.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.